123 related articles for article (PubMed ID: 1604238)
1. Soluble interleukin-2 receptor levels and immune activation in patients with schistosomiasis and carcinoma of the urinary bladder.
Raziuddin S; Shetty S; Ibrahim A
Scand J Immunol; 1992 Jun; 35(6):637-41. PubMed ID: 1604238
[TBL] [Abstract][Full Text] [Related]
2. Phenotype, activation and lymphokine secretion by gamma/delta T lymphocytes from schistosomiasis and carcinoma of the urinary bladder.
Raziuddin S; Shetty S; Ibrahim A
Eur J Immunol; 1992 Feb; 22(2):309-14. PubMed ID: 1531634
[TBL] [Abstract][Full Text] [Related]
3. T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis.
Raziuddin S; Shetty S; Ibrahim A
J Clin Immunol; 1991 Mar; 11(2):103-13. PubMed ID: 1905303
[TBL] [Abstract][Full Text] [Related]
4. Activated CD4-positive T-lymphocytes and impaired cell-mediated immunity in patients with carcinoma of the urinary bladder with schistosomiasis.
Raziuddin S; Shetty S; Ibrahim A; Patil K
Cancer; 1990 Feb; 65(4):931-9. PubMed ID: 1688730
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
8. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
10. Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.
Bock GH; Ongkingco JR; Patterson LT; Ruley J; Schroepfer LR; Nelson DL
Pediatr Nephrol; 1993 Oct; 7(5):523-8. PubMed ID: 8251314
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
13. In vivo CD3+CD25+ lymphocyte subpopulation is down-regulated without increased serum-soluble interleukin-2 receptor (sIL-2R) by gonadotropin releasing hormone agonist (GnRH-a).
Ho HN; Wu MY; Chen HF; Chao KH; Yang YS; Huang SC; Lee TY; Gill TJ
Am J Reprod Immunol; 1995 Jan; 33(1):134-9. PubMed ID: 7619228
[TBL] [Abstract][Full Text] [Related]
14. The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
Dooley MA; Cush JJ; Lipsky PE; Dawson DV; Pisetsky DS
J Rheumatol; 1993 Nov; 20(11):1857-62. PubMed ID: 8308770
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease.
Proujansky R; Carpenter AB
J Pediatr Gastroenterol Nutr; 1991 Oct; 13(3):277-84. PubMed ID: 1791504
[TBL] [Abstract][Full Text] [Related]
17. Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis.
Lipnick RN; Sfikakis PP; Klipple GL; Tsokos GC
Clin Immunol Immunopathol; 1993 Jul; 68(1):64-7. PubMed ID: 8513595
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
19. IL-2 regulation of soluble IL-2 receptor levels following thermal injury.
Teodorczyk-Injeyan JA; Sparkes BG; Lalani S; Peters WJ; Mills GB
Clin Exp Immunol; 1992 Oct; 90(1):36-42. PubMed ID: 1382903
[TBL] [Abstract][Full Text] [Related]
20. Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation.
Young JB; Windsor NT; Smart FW; Kleiman NS; Weilbaecher DG; Noon GP; Nelson DL; Lawrence EC
Transplantation; 1991 Mar; 51(3):636-41. PubMed ID: 2006520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
